FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Rudick

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Irene L Katzan; Richard A Rudick
Author response to comment on "time to integrate clinical and research informatics".
Edru Erbayat Altay; Elizabeth Fisher; Claire Hara-Cleaver; Stephen E Jones; Jar-Chi Lee; Richard A Rudick
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.
Robert A Bermel; Elizabeth Fisher; Pamela Foulds; Robert Hyde; Jack H Simon; Xiaojun You; Richard A Rudick
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Rudick (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Irene L Katzan; Richard A Rudick
Author response to comment on "time to integrate clinical and research informatics".
Science translational medicine 2013;5(179):179lr1.
2013: Edru Erbayat Altay; Elizabeth Fisher; Claire Hara-Cleaver; Stephen E Jones; Jar-Chi Lee; Richard A Rudick
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.
JAMA neurology 2013;70(3):338-44.
2013: Robert A Bermel; Elizabeth Fisher; Pamela Foulds; Robert Hyde; Jack H Simon; Xiaojun You; Richard A Rudick
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
Annals of neurology 2013;73(1):95-103.
2012: Daniel Ontaneda; Richard A Rudick; Jeffrey A Cohen; Claire Hara-Cleaver; Robert A Bermel
Early tolerability and safety of fingolimod in clinical practice.
Journal of the neurological sciences 2012;323(1-2):167-72.
2012: Irene L Katzan; Richard A Rudick
Time to integrate clinical and research informatics.
Science translational medicine 2012;4(162):162fs41.
2012: Richard A Rudick
MS clinical trials: what can subgroup analyses teach us?
Lancet neurology 2012;11(5):386-8.
2011: Joana A Zula; Holly C Green; Richard M Ransohoff; Richard A Rudick; George R Stark; Anette H H van Boxel-Dezaire
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(49):19689-94.
2011: Megan Hyland; Richard A Rudick
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
Current opinion in neurology 2011;24(3):255-61.
2011: Richard A Rudick; Susan E Goelz
Beta-interferon for multiple sclerosis.
Experimental cell research 2011;317(9):1301-11.
2011: Richard A Rudick; M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jie Na; Jennifer Shrock; Anupama Josyula; Elizabeth Fisher; Richard M Ransohoff
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
PloS one 2011;6(5):e19262.
2011: Deborah M Miller; Shirley M Moore; Robert J Fox; Ashish Atreja; Alex Z Fu; Jar-Chi Lee; Welf Saupe; Maria Stadtler; Swati Chakraborty; C M Harris; Richard A Rudick
Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2011;17(1):5-13.
2010: Richard A Rudick; Jar-Chi Lee; Gary R Cutter; Deborah M Miller; Dennis N Bourdette; Bianca Weinstock-Guttman; Robert Hyde; Hao Zhang; Xiaojun You
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.
Archives of neurology 2010;67(11):1329-35.
2010: Richard A Rudick
Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?
Nature reviews. Neurology 2010;6(9):472-4.
2010: Richard A Rudick; Paul W O'Connor; Chris H Polman; AD Goodman; Soma S Ray; Nancy M Griffith; Stephanie A Jurgensen; Leonid Gorelik; Fiona Forrestal; Alfred W Sandrock; Susan E Goelz
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Annals of neurology 2010;68(3):304-10.
2010: Richard A Rudick; Ludwig Kappos
Measuring disability in relapsing-remitting MS.
Neurology 2010;75(4):296-7.
2010: Ernst-Wilhelm Radue; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Richard A Rudick; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Elizabeth Fisher; Athina Papadopoulou; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Journal of the neurological sciences 2010;292(1-2):28-35.
2010: D Miller; Richard A Rudick; Michael Hutchinson
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.
Neurology 2010;74 Suppl 3():S24-35.
2009: M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jennifer Shrock; Anupama Josyula; Joerg Schlaak; Swathi Chakraborthy; Nie Ja; Richard M Ransohoff; Richard A Rudick
Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.
Annals of the New York Academy of Sciences 2009;1182():58-68.
2009: Richard A Rudick; Elizabeth Fisher
Do interferon beta-1b and glatiramer acetate grow brain?
Lancet neurology 2009;8(12):1085-6; author reply 1086-7.
2009: Richard A Rudick; Delos M Cosgrove
A radical proposal: integrate clinical investigation into the U.S. health care system.
Science translational medicine 2009;1(4):4cm4.
2009: Richard A Rudick; Chris H Polman; Jeffrey A Cohen; M K Walton; A E Miller; Christian Confavreux; Fred D Lublin; Michael Hutchinson; P W O'Connor; S R Schwid; Laura J Balcer; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(8):984-97.
2009: Richard A Rudick; A Pace; M R S Rani; R Hyde; M Panzara; S Appachi; J Shrock; S L Maurer; Peter A Calabresi; C Confavreux; S L Galetta; F D Lublin; E-W Radue; Richard M Ransohoff
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
Neurology 2009;72(23):1989-93.
2009: Richard A Rudick; Chris H Polman
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
Lancet neurology 2009;8(6):545-59.
2009: Michael Hutchinson; Ludwig Kappos; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Steven L Galetta; Eva Havrdova; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel Wynn; Frances Lynn; Michael A Panzara
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Journal of neurology 2009;256(3):405-15.
2008: Richard A Rudick; Sha Mi; Alfred W Sandrock
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.
Expert opinion on biological therapy 2008;8(10):1561-70.
2008: Elizabeth Fisher; Jar-Chi Lee; Kunio Nakamura; Richard A Rudick
Gray matter atrophy in multiple sclerosis: a longitudinal study.
Annals of neurology 2008;64(3):255-65.
2008: Richard A Rudick; Michael A Panzara
Natalizumab for the treatment of relapsing multiple sclerosis.
Biologics : targets & therapy 2008;2(2):189-99.
2007: M R Sandhya Rani; Jennifer Shrock; Swathi Appachi; Richard A Rudick; Bryan R G Williams; Richard M Ransohoff
Novel interferon-beta-induced gene expression in peripheral blood cells.
Journal of leukocyte biology 2007;82(5):1353-60.
2007: Peter A Calabresi; Gavin Giovannoni; Christian Confavreux; Steven L Galetta; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Fred D Lublin; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology 2007;69(14):1391-403.
2007: Robert A Bermel; Richard A Rudick
Interferon-beta treatment for multiple sclerosis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(4):633-46.
2007: Ranjan Dutta; Jennifer McDonough; Ansi Chang; Lakshman Swamy; Alan Siu; Grahame J Kidd; Richard A Rudick; Károly Mirnics; Bruce D Trapp
Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients.
Brain : a journal of neurology 2007;130(Pt 10):2566-76.
2007: Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Annals of neurology 2007;62(4):335-46.
2007: Elizabeth Fisher; Ansi Chang; Robert J Fox; Jean A Tkach; Therese Svarovsky; Kunio Nakamura; Richard A Rudick; Bruce D Trapp
Imaging correlates of axonal swelling in chronic multiple sclerosis brains.
Annals of neurology 2007;62(3):219-28.
2007: Ludwig Kappos; David Bates; Hans-Peter Hartung; Eva Havrdova; David Miller; Chris H Polman; Mads Ravnborg; Stephen L Hauser; Richard A Rudick; Howard L Weiner; Paul W O'Connor; John King; Ernst-Wilhelm Radue; Tarek A Yousry; Eugene O Major; David B Clifford
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet neurology 2007;6(5):431-41.
2007: David H Miller; Derek Soon; Kryshani T M Fernando; David G MacManus; Gareth Barker; Tarek A Yousry; Elizabeth Fisher; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ludwig Kappos; Michael Hutchinson; Eva Havrdova; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Richard A Rudick; Frances Lynn; Michael A Panzara; Alfred W Sandrock
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Neurology 2007;68(17):1390-401.
2007: Laura J Balcer; Steven L Galetta; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Neurology 2007;68(16):1299-304.
2007: Carol E Blixen; Klara K Papp; Alan L Hull; Richard A Rudick; Katrina A Bramstedt
Developing a mentorship program for clinical researchers.
The Journal of continuing education in the health professions 2007;27(2):86-93.
2006: Richard A Rudick; Jar-Chi Lee; Jack Simon; Elizabeth Fisher
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
Annals of neurology 2006;60(2):236-42.
2006: Richard A Rudick
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(3):143-6.
2006: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
The New England journal of medicine 2006;354(9):911-23.
2006: Ranjan Dutta; Jennifer McDonough; Xinghua Yin; John Peterson; Ansi Chang; Thalia Torres; Tatyana I Gudz; Wendy B Macklin; David A Lewis; Robert J Fox; Richard A Rudick; Károly Mirnics; Bruce D Trapp
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Annals of neurology 2006;59(3):478-89.
2006: Robert J Fox; Pia Kivisäkk; Jar-Chi Lee; Barbara Tucky; Claudia F Lucchinetti; Richard A Rudick; Richard M Ransohoff
Chemokine receptors as biomarkers in multiple sclerosis.
Disease markers 2006;22(4):227-33.
2006: Ruth Ann Marrie; Richard A Rudick
Drug Insight: interferon treatment in multiple sclerosis.
Nature clinical practice. Neurology 2006;2(1):34-44.
2005: Richard A Rudick; Gary R Cutter; Monika L Baier; Bianca Weinstock-Guttman; Michele K Mass; Elizabeth Fisher; Deborah M Miller; Alfred W Sandrock
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(6):626-34.
2005: Clara M Pelfrey; Ioana R Moldovan; anne cotleur; Natacha Zamor; Richard A Rudick
Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
Journal of neuroimmunology 2005;167(1-2):190-203.
2005: Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick Munschauer; Rohit Bakshi
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.
Archives of neurology 2005;62(9):1371-6.
2005: Ilka Warshawsky; Richard A Rudick; Susan M Staugaitis; Marvin R Natowicz
Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation.
Annals of neurology 2005;58(3):470-3.
2005: Robert M Herndon; Richard A Rudick; Frederick Munschauer; Michele K Mass; Andres M Salazar; Michael E Coats; Robert Labutta; John R Richert; Stanley L Cohan; Claude P Genain; Donald Goodkin; Martin Toal; Katherine Riester
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(4):409-19.
2005: Ioana R Moldovan; Richard A Rudick; anne cotleur; S E Born; Jar-Chi Lee; Matthew T Karafa; Clara M Pelfrey
Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing--remitting multiple sclerosis patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(3):251-60.
2005: Robert J Fox; Elizabeth Fisher; Jean A Tkach; Jar-Chi Lee; Jeffrey A Cohen; Richard A Rudick
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(2):140-5.
2005: Monika L Baier; Gary R Cutter; Richard A Rudick; D Miller; Jeffrey A Cohen; Bianca Weinstock-Guttman; Michele K Mass; Laura J Balcer
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
Neurology 2005;64(6):992-5.
2005: Ruth Ann Marrie; Elizabeth Fisher; Deborah M Miller; Jar-Chi Lee; Richard A Rudick
Association of fatigue and brain atrophy in multiple sclerosis.
Journal of the neurological sciences 2005;228(2):161-6.
2005: Martin Hardmeier; Stefan Wagenpfeil; Peter Freitag; E Fisher; Richard A Rudick; MF Kooijmans; Michel Clanet; Ernst-Wilhelm Radue; Ludwig Kappos
Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
Neurology 2005;64(2):236-40.
2004: Richard A Rudick; Jar-Chi Lee; Jack Simon; Richard M Ransohoff; Elizabeth Fisher
Defining interferon beta response status in multiple sclerosis patients.
Annals of neurology 2004;56(4):548-55.
2004: Richard A Rudick; Alfred W Sandrock
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Expert review of neurotherapeutics 2004;4(4):571-80.
2004: Richard A Rudick
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 2004;14(3 Suppl):54S-64S.
2004: Robert J Fox; Richard A Rudick
Multiple sclerosis: disease markers accelerate progress.
Lancet neurology 2004;3(1):10.
2003: Martin Hardmeier; Stefan Wagenpfeil; Peter Freitag; Elizabeth Fisher; Richard A Rudick; Mariska Kooijmans-Coutinho; Michel Clanet; Ernst-Wilhelm Radue; Ludwig Kappos
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
Archives of neurology 2003;60(12):1736-9.
2003: Bianca Weinstock-Guttman; Monika Baier; R Stockton; A Weinstock; T Justinger; Frederick Munschauer; Carol Brownscheidle; J Williams; E Fisher; D Miller; Richard A Rudick
Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(5):529-34.
2003: Pia Kivisäkk; anne cotleur; Jar-Chi Lee; Richard A Rudick; Richard M Ransohoff
Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.
Journal of neuroimmunology 2003;141(1-2):150-4.
2003: Ioana R Moldovan; Richard A Rudick; anne cotleur; Sarah E Born; Jar-Chi Lee; Matthew T Karafa; Clara M Pelfrey
Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.
Journal of neuroimmunology 2003;141(1-2):132-40.
2003: Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.
Journal of neurovirology 2003;9(3):291-9.
2003: Richard A Rudick; Diane L Cookfair; Jack Griffin; Stephen Hauser; Steven Piantadosi
Interferons in relapsing remitting multiple sclerosis.
Lancet 2003;361(9371):1824; author reply 1824-5.
2003: Pia Kivisäkk; Zhugong Liu; Corinna Trebst; Barbara Tucky; Lijun Wu; Johnny Stine; Matthias Mack; Richard A Rudick; James J Campbell; Richard M Ransohoff
Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes.
Methods (San Diego, Calif.) 2003;29(4):319-25.
2003: Richard A Rudick
Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(2):210-2.
2003: Deborah M Miller; Richard A Rudick; Monika L Baier; Gary R Cutter; David S Doughtery; Bianca Weinstock-Guttman; Michele K Mass; Elizabeth Fisher; Nancy Simonian
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(1):1-5.
2002: Elizabeth Fisher; Richard A Rudick; Jack H Simon; Gary R Cutter; Monika L Baier; Jar-Chi Lee; D Miller; Bianca Weinstock-Guttman; Michele K Mass; DS Dougherty; Nancy Simonian
Eight-year follow-up study of brain atrophy in patients with MS.
Neurology 2002;59(9):1412-20.
2002: Richard A Rudick; Gary R Cutter; Stephen C Reingold
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):359-65.
2002: Jeffrey A Cohen; Gary R Cutter; Jill Fischer; AD Goodman; FR Heidenreich; MF Kooijmans; Alfred W Sandrock; Richard A Rudick; Jack H Simon; Nancy Simonian; EC Tsao; J N Whitaker
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Neurology 2002;59(5):679-87.
2002: Clara M Pelfrey; anne cotleur; Jar-Chi Lee; Richard A Rudick
Sex differences in cytokine responses to myelin peptides in multiple sclerosis.
Journal of neuroimmunology 2002;130(1-2):211-23.
2002: Pia Kivisäkk; Corinna Trebst; Zhugong Liu; Barbara Tucky; Torben Lykke Sørensen; Richard A Rudick; Matthias Mack; Richard M Ransohoff
T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.
Clinical and experimental immunology 2002;129(3):510-8.
2002: Robert J Fox; Elizabeth Fisher; Richard A Rudick
Disease modifying therapies in multiple sclerosis.
Neurology 2002;59(3):471-2; author reply 472-3.
2002: Ansi Chang; Wallace W Tourtellotte; Richard A Rudick; Bruce D Trapp
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis.
The New England journal of medicine 2002;346(3):165-73.
2001: Richard A Rudick; Donald Goodkin; Lawrence D Jacobs; Diane L Cookfair; Robert M Herndon; John R Richert; AM Salazar; Jill Fischer; CV Granger; Jack H Simon; J J Alam; Nancy Simonian; MK Campion; DM Bartoszak; Dennis N Bourdette; J Braiman; Carol Brownscheidle; Michael E Coats; Stanley L Cohan; DS Dougherty; R Philip Kinkel; Michele K Mass; Frederick Munschauer; Roger Priore; P M Pullicino; B J Scherokman; B Weistock-Guttman; Ruth H Whitham
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.
Neurology 2001;57(12 Suppl 5):S25-30.
2001: Carl Bjartmar; R Philip Kinkel; Grahame J Kidd; Richard A Rudick; Bruce D Trapp
Axonal loss in normal-appearing white matter in a patient with acute MS.
Neurology 2001;57(7):1248-52.
2001: Richard A Rudick; Gary R Cutter; Monika L Baier; Elizabeth Fisher; D Dougherty; Bianca Weinstock-Guttman; Michele K Mass; D Miller; Nancy Simonian
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
Neurology 2001;56(10):1324-30.
2001: Zhugong Liu; Clara M Pelfrey; anne cotleur; Jar-Chi Lee; Richard A Rudick
Immunomodulatory effects of interferon beta-1a in multiple sclerosis.
Journal of neuroimmunology 2001;112(1-2):153-62.
2000: Laura J Balcer; Monika L Baier; A M Kunkle; Richard A Rudick; Bianca Weinstock-Guttman; Nancy Simonian; Steven L Galetta; Gary R Cutter; Maureen G Maguire
Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25).
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(6):382-5.
2000: Elizabeth Fisher; Richard A Rudick; Gary R Cutter; Monika L Baier; D Miller; Bianca Weinstock-Guttman; Michele K Mass; DS Dougherty; Nancy Simonian
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(6):373-7.
2000: Richard A Rudick; Elizabeth Fisher; Jar-Chi Lee; J T Duda; Jack Simon
Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(6):365-72.
2000: Carl Bjartmar; Grahame J Kidd; Sverre Mörk; Richard A Rudick; Bruce D Trapp
Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
Annals of neurology 2000;48(6):893-901.
2000: Jill Fischer; Roger Priore; Lawrence D Jacobs; Diane L Cookfair; Richard A Rudick; Robert M Herndon; John R Richert; AM Salazar; Donald Goodkin; CV Granger; Jack H Simon; J H Grafman; M D Lezak; K M O'Reilly Hovey; K K Perkins; D Barilla-Clark; M Schacter; D W Shucard; A L Davidson; Karl E Wende; Dennis N Bourdette; Mariska Kooijmans-Coutinho
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.
Annals of neurology 2000;48(6):885-92.
2000: Deborah M Miller; Richard A Rudick; Gary R Cutter; Monika L Baier; Jill Fischer
Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
Archives of neurology 2000;57(9):1319-24.
2000: Deborah M Miller; Bianca Weinstock-Guttman; F Béthoux; Jar-Chi Lee; G Beck; V Block; L Durelli; L LaMantia; D Barnes; Finn Sellebjerg; Richard A Rudick
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(4):267-73.
2000: Clara M Pelfrey; Richard A Rudick; anne cotleur; Jar-Chi Lee; Magdalena Tary-Lehmann; Paul V Lehmann
Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(3):1641-51.
2000: Jack H Simon; JM Lull; Lawrence D Jacobs; Richard A Rudick; Diane L Cookfair; Robert M Herndon; John R Richert; AM Salazar; Jeanelle Sheeder; D Miller; K McCabe; A Serra; MK Campion; Jill Fischer; Donald Goodkin; Nancy Simonian; M Lajaunie; Karl E Wende; AL Martens-Davidson; R Philip Kinkel; Frederick Munschauer
A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
Neurology 2000;55(2):185-92.
1999: Richard A Rudick; Elizabeth Fisher; Jar-Chi Lee; J Simon; L Jacobs
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.
Neurology 1999;53(8):1698-704.
1999: Richard A Rudick
Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Archives of neurology 1999;56(9):1079-84.
1999: Jill Fischer; Richard A Rudick; Gary R Cutter; Stephen C Reingold
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.
Multiple sclerosis (Houndmills, Basingstoke, England) 1999;5(4):244-50.
1999: Jack H Simon; Lawrence D Jacobs; MK Campion; Richard A Rudick; Diane L Cookfair; Robert M Herndon; John R Richert; AM Salazar; Jill Fischer; Donald Goodkin; Nancy Simonian; M Lajaunie; David E Miller; Karl E Wende; AL Martens-Davidson; R Philip Kinkel; Frederick Munschauer; Carol Brownscheidle
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Neurology 1999;53(1):139-48.
1999: Richard A Rudick; A Goodman; Robert M Herndon; Hillel Panitch
Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment.
Journal of neuroimmunology 1999;98(1):22-8.
1999: Bruce D Trapp; Richard M Ransohoff; Richard A Rudick
Axonal pathology in multiple sclerosis: relationship to neurologic disability.
Current opinion in neurology 1999;12(3):295-302.
1999: Gary R Cutter; M L Baier; Richard A Rudick; Diane L Cookfair; Jill Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; Christian Confavreux; G W Ellison; Fred D Lublin; A E Miller; Stephen Rao; Stephen C Reingold; A Thompson; E Willoughby
Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
Brain : a journal of neurology 1999;122 ( Pt 5)():871-82.
1999: Richard A Rudick; Diane L Cookfair; Nancy Simonian; Richard M Ransohoff; John R Richert; Lawrence D Jacobs; Robert M Herndon; AM Salazar; Jill Fischer; CV Granger; Donald Goodkin; Jack H Simon; DM Bartoszak; Dennis N Bourdette; J Braiman; Carol Brownscheidle; Michael E Coats; Stanley L Cohan; DS Dougherty; R Philip Kinkel; Michele K Mass; F E Munchsauer; K O'Reilly; Roger Priore; Ruth H Whitham
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Journal of neuroimmunology 1999;93(1-2):8-14.
1998: Donald Goodkin; Roger Priore; Karl E Wende; MK Campion; Dennis N Bourdette; Robert M Herndon; Jill Fischer; Lawrence D Jacobs; Diane L Cookfair; Richard A Rudick; John R Richert; A M Salazar; CV Granger; Jack H Simon; J J Alam; DM Bartoszak; J Braiman; Carol Brownscheidle; Michael E Coats; Stanley L Cohan; DS Dougherty; R Philip Kinkel; Michele K Mass; Frederick Munschauer; Ruth H Whitham
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Multiple sclerosis (Houndmills, Basingstoke, England) 1998;4(6):480-6.
1998: Richard A Rudick; Richard M Ransohoff; Jar-Chi Lee; R Peppler; Min Yu; PM Mathisen; Vincent K Tuohy
In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis.
Neurology 1998;50(5):1294-300.
1998: Richard A Rudick; Nancy Simonian; J A Alam; MK Campion; J O Scaramucci; W Jones; Michael E Coats; Donald Goodkin; Bianca Weinstock-Guttman; Robert M Herndon; Michele K Mass; John R Richert; AM Salazar; Frederick Munschauer; Diane L Cookfair; Jack H Simon; Lawrence D Jacobs
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)
Neurology 1998;50(5):1266-72.
1998: Bruce D Trapp; J Peterson; Richard M Ransohoff; Richard A Rudick; Sverre Mörk; Lars Bö
Axonal transection in the lesions of multiple sclerosis.
The New England journal of medicine 1998;338(5):278-85.
1998: Jack H Simon; Lawrence D Jacobs; MK Campion; Karl E Wende; Nancy Simonian; Diane L Cookfair; Richard A Rudick; Robert M Herndon; John R Richert; AM Salazar; J J Alam; Jill Fischer; Donald Goodkin; CV Granger; M Lajaunie; AL Martens-Davidson; M Meyer; Jeanelle Sheeder; K Choi; Ann L Scherzinger; DM Bartoszak; Dennis N Bourdette; J Braiman; Carol Brownscheidle; Ruth H Whitham
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Annals of neurology 1998;43(1):79-87.
1997: Richard A Rudick; J A Cohen; Bianca Weinstock-Guttman; R Philip Kinkel; Richard M Ransohoff
Management of multiple sclerosis.
The New England journal of medicine 1997;337(22):1604-11.
1997: James E Aikens; Jill Fischer; M Namey; Richard A Rudick
A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis.
Journal of behavioral medicine 1997;20(5):433-45.
1997: Richard A Rudick; J Antel; Christian Confavreux; Gary R Cutter; G Ellison; J Fischer; Fred D Lublin; A Miller; J Petkau; Stephen Rao; Stephen C Reingold; K Syndulko; A Thompson; J Wallenberg; Brian G Weinshenker; E Willoughby
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.
Annals of neurology 1997;42(3):379-82.
1997: Bianca Weinstock-Guttman; Richard A Rudick
Prescribing recommendations for interferon-Beta in multiple sclerosis.
CNS drugs 1997;8(2):102-12.
1997: Richard A Rudick; Donald Goodkin; Lawrence D Jacobs; Diane L Cookfair; Robert M Herndon; John R Richert; AM Salazar; Jill Fischer; CV Granger; Jack H Simon; J J Alam; Nancy Simonian; MK Campion; DM Bartoszak; Dennis N Bourdette; J Braiman; Carol Brownscheidle; Michael E Coats; Stanley L Cohan; DS Dougherty; R Philip Kinkel; Michele K Mass; Frederick Munschauer; Roger Priore; Ruth H Whitham
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Neurology 1997;49(2):358-63.
1996: Donald Goodkin; Richard A Rudick; S VanderBrug Medendorp; M M Daughtry; C Van Dyke
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs.
Neurology 1996;47(5):1153-7.
1996: Richard A Rudick; Richard M Ransohoff; R Peppler; S VanderBrug Medendorp; P Lehmann; J Alam
Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
Annals of neurology 1996;40(4):618-27.
1996: Richard A Rudick; J Antel; C Confavreux; Gary R Cutter; G Ellison; J Fischer; Fred D Lublin; A Miller; J Petkau; Stephen Rao; Stephen C Reingold; K Syndulko; A Thompson; J Wallenberg; B Weinshenker; E Willoughby
Clinical outcomes assessment in multiple sclerosis.
Annals of neurology 1996;40(3):469-79.
1996: Lawrence D Jacobs; Diane L Cookfair; Richard A Rudick; Robert M Herndon; John R Richert; AM Salazar; Jill Fischer; Donald Goodkin; C V Granger; Jack H Simon; J J Alam; DM Bartoszak; Dennis N Bourdette; J Braiman; Carol Brownscheidle; Michael E Coats; Stanley L Cohan; DS Dougherty; R Philip Kinkel; Michele K Mass; Frederick Munschauer; Roger Priore; PM Pullicino; B J Scherokman; Ruth H Whitham
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
Annals of neurology 1996;39(3):285-94.
1995: Richard A Rudick; S V Medendorp; M Namey; S Boyle; J Fischer
Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains.
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1(3):150-5.
1995: Lawrence D Jacobs; Diane L Cookfair; Richard A Rudick; R M Herndon; J R Richert; A M Salazar; Jill Fischer; Donald Goodkin; C V Granger; Jack H Simon
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1(2):118-35.
1995: Richard A Rudick; R M Ransohoff
Biologic effects of interferons: relevance to multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1 Suppl 1():S12-6.
1995: Donald Goodkin; Richard A Rudick; S VanderBrug Medendorp; M M Daughtry; K M Schwetz; J Fischer; C Van Dyke
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
Annals of neurology 1995;37(1):30-40.
1995: Bianca Weinstock-Guttman; Richard M Ransohoff; R Philip Kinkel; Richard A Rudick
The interferons: biological effects, mechanisms of action, and use in multiple sclerosis.
Annals of neurology 1995;37(1):7-15.
1993: Richard A Rudick; C S Carpenter; Diane L Cookfair; Vincent K Tuohy; Richard M Ransohoff
In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta.
Neurology 1993;43(10):2080-7.
1993: Donald Goodkin; Richard A Rudick; R Philip Kinkel; Richard M Ransohoff
Corticosteroids and optic neuritis.
Neurology 1993;43(3 Pt 1):631-2; author reply 633-4.
1992: Donald Goodkin; Richard A Rudick; S VanderBrug Medendorp; T Greene; K M Schwetz; J Fischer; M M Daughtry; J Ross; C Van Dyke
Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
The Online journal of current clinical trials 1992;Doc No 19():[7723 words; 89 paragraphs].
1992: Richard M Ransohoff; Vincent K Tuohy; Barbara P Barna; Richard A Rudick
Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo.
Journal of neuroimmunology 1992;37(3):169-76.
1991: Richard M Ransohoff; C Devajyothi; ML Estes; G Babcock; Richard A Rudick; E M Frohman; Barbara P Barna
Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line.
Journal of neuroimmunology 1991;33(2):103-12.
1991: G L Stanescu; A R Swick; Vincent K Tuohy; Richard A Rudick
Sensitive competitive-binding ELISAs for quantifying free kappa and lambda light chains in cerebrospinal fluid.
Journal of clinical laboratory analysis 1991;5(3):206-11.
1989: Richard A Rudick; C A French; D Breton; G W Williams
Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests.
Neurology 1989;39(7):964-8.